Discrepancies in three commercial prognostic breast cancer assays used in adjuvant chemotherapy decisions.


84 Background: OT (Oncotype DX), MS (Mammostrat) and MP (Mammaprint) are three prognostic measures of breast cancer recurrence risk. All three were retrospectively validated in large patient cohorts and are now used when deciding on risk-reducing adjuvant chemotherapy. Our objective was to directly compare these three assays and their potential for… (More)
DOI: 10.1200/jco.2014.32.26_suppl.84


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics